carmustine has been researched along with Cancer, Second Primary in 18 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 9.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 5.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 5.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "Six patients, four with Hodgkin's disease and two with non-Hodgkin lymphomas, developed leukemic complications, myelodysplasia (MDS) in four cases and overt acute myeloid leukemia (AML) in two." | 2.68 | High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. ( Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J, 1997) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "The incidence of and risk factors for second cancer development in these patients have not been well studied." | 1.35 | Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. ( Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S, 2009) |
| "Cytogenetic analysis showed complex chromosomal abnormalities including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related hematologic malignancies." | 1.31 | A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. ( Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ, 2002) |
| "Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable." | 1.31 | Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 1.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, T | 1 |
| Nishikawa, R | 2 |
| Sugiyama, K | 1 |
| Nonoguchi, N | 1 |
| Kawabata, N | 1 |
| Mishima, K | 1 |
| Adachi, J | 1 |
| Kurisu, K | 1 |
| Yamasaki, F | 1 |
| Tominaga, T | 1 |
| Kumabe, T | 1 |
| Ueki, K | 1 |
| Higuchi, F | 1 |
| Yamamoto, T | 1 |
| Ishikawa, E | 1 |
| Takeshima, H | 1 |
| Yamashita, S | 1 |
| Arita, K | 1 |
| Hirano, H | 1 |
| Yamada, S | 1 |
| Matsutani, M | 1 |
| Seshadri, T | 1 |
| Pintilie, M | 1 |
| Kuruvilla, J | 1 |
| Keating, A | 1 |
| Tsang, R | 1 |
| Zadeh, S | 1 |
| Crump, M | 1 |
| Wang, B | 1 |
| Ren, C | 1 |
| Zhang, W | 1 |
| Ma, X | 1 |
| Xia, B | 1 |
| Sheng, Z | 1 |
| Jang, GD | 1 |
| Kim, SW | 1 |
| Suh, CW | 1 |
| Kim, EK | 1 |
| Bahng, HS | 1 |
| Jeong, YH | 1 |
| Park, IG | 1 |
| Kim, WK | 1 |
| Kim, SH | 1 |
| Suh, EJ | 1 |
| Park, CJ | 1 |
| Ji, HS | 1 |
| Lee, JS | 1 |
| Wadhwa, PD | 1 |
| Fu, P | 1 |
| Koc, ON | 1 |
| Cooper, BW | 1 |
| Fox, RM | 1 |
| Creger, RJ | 1 |
| Bajor, DL | 1 |
| Bedi, T | 1 |
| Laughlin, MJ | 1 |
| Payne, J | 1 |
| Gerson, SL | 1 |
| Lazarus, HM | 1 |
| Strobel, ES | 1 |
| Bauchmüller, K | 1 |
| Schmitt-Gräff, A | 1 |
| Engelhardt, M | 1 |
| Nicolardi, L | 1 |
| DeAngelis, LM | 1 |
| Dreger, P | 1 |
| Brand, R | 1 |
| Michallet, M | 1 |
| Mercadal, S | 1 |
| Briones, J | 1 |
| Xicoy, B | 1 |
| Pedro, C | 1 |
| Escoda, L | 1 |
| Estany, C | 1 |
| Camós, M | 1 |
| Colomo, L | 1 |
| Espinosa, I | 1 |
| Martínez, S | 1 |
| Ribera, JM | 1 |
| Martino, R | 1 |
| Gutiérrez-García, G | 1 |
| Montserrat, E | 1 |
| López-Guillermo, A | 1 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Oken, MM | 1 |
| Harrington, DP | 1 |
| Abramson, N | 1 |
| Kyle, RA | 1 |
| Knospe, W | 1 |
| Glick, JH | 1 |
| Pedersen-Bjergaard, J | 1 |
| Pedersen, M | 1 |
| Myhre, J | 1 |
| Geisler, C | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 1 |
| Decaudin, D | 1 |
| Brousse, N | 1 |
| Brice, P | 1 |
| Haioun, C | 1 |
| Bourhis, JH | 1 |
| Morel, P | 1 |
| Van Hoof, A | 1 |
| Souleau, B | 1 |
| Quesnel, B | 1 |
| Gisselbrecht, C | 1 |
| Berglund, A | 1 |
| Enblad, G | 1 |
| Carlson, K | 1 |
| Glimelius, B | 1 |
| Hagberg, H | 1 |
| Meloni, G | 1 |
| Proia, A | 1 |
| Guerrisi, V | 1 |
| Cordone, I | 1 |
| De Cuia, R | 1 |
| Fenu, S | 1 |
| Mauro, FR | 1 |
| Pescarmona, E | 1 |
| Reato, G | 1 |
| Mandelli, F | 1 |
| Wheeler, C | 1 |
| Khurshid, A | 1 |
| Ibrahim, J | 1 |
| Elias, A | 1 |
| Mauch, P | 1 |
| Ault, K | 1 |
| Antin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for carmustine and Cancer, Second Primary
| Article | Year |
|---|---|
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Top | 2013 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Ca | 2007 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
6 trials available for carmustine and Cancer, Second Primary
8 other studies available for carmustine and Cancer, Second Primary
| Article | Year |
|---|---|
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hema | 2009 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2002 |
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality | 2005 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2000 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2001 |